These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 36167501)
1. Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome. Jonak CR; Pedapati EV; Schmitt LM; Assad SA; Sandhu MS; DeStefano L; Ethridge L; Razak KA; Sweeney JA; Binder DK; Erickson CA J Neurodev Disord; 2022 Sep; 14(1):52. PubMed ID: 36167501 [TBL] [Abstract][Full Text] [Related]
2. GABA-B Agonist Baclofen Normalizes Auditory-Evoked Neural Oscillations and Behavioral Deficits in the Sinclair D; Featherstone R; Naschek M; Nam J; Du A; Wright S; Pance K; Melnychenko O; Weger R; Akuzawa S; Matsumoto M; Siegel SJ eNeuro; 2017; 4(1):. PubMed ID: 28451631 [TBL] [Abstract][Full Text] [Related]
3. Phenotypic analysis of multielectrode array EEG biomarkers in developing and adult male Fmr1 KO mice. Jonak CR; Assad SA; Garcia TA; Sandhu MS; Rumschlag JA; Razak KA; Binder DK Neurobiol Dis; 2024 Jun; 195():106496. PubMed ID: 38582333 [TBL] [Abstract][Full Text] [Related]
4. Paradoxical effect of baclofen on social behavior in the fragile X syndrome mouse model. Zeidler S; Pop AS; Jaafar IA; de Boer H; Buijsen RAM; de Esch CEF; Nieuwenhuizen-Bakker I; Hukema RK; Willemsen R Brain Behav; 2018 Jun; 8(6):e00991. PubMed ID: 29785777 [TBL] [Abstract][Full Text] [Related]
5. The PDE10A Inhibitor TAK-063 Reverses Sound-Evoked EEG Abnormalities in a Mouse Model of Fragile X Syndrome. Jonak CR; Sandhu MS; Assad SA; Barbosa JA; Makhija M; Binder DK Neurotherapeutics; 2021 Apr; 18(2):1175-1187. PubMed ID: 33594533 [TBL] [Abstract][Full Text] [Related]
6. Translation-relevant EEG phenotypes in a mouse model of Fragile X Syndrome. Lovelace JW; Ethell IM; Binder DK; Razak KA Neurobiol Dis; 2018 Jul; 115():39-48. PubMed ID: 29605426 [TBL] [Abstract][Full Text] [Related]
7. R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome. Qin M; Huang T; Kader M; Krych L; Xia Z; Burlin T; Zeidler Z; Zhao T; Smith CB Int J Neuropsychopharmacol; 2015 Mar; 18(9):. PubMed ID: 25820841 [TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome. Lovelace JW; Wen TH; Reinhard S; Hsu MS; Sidhu H; Ethell IM; Binder DK; Razak KA Neurobiol Dis; 2016 May; 89():126-35. PubMed ID: 26850918 [TBL] [Abstract][Full Text] [Related]
9. Multielectrode array analysis of EEG biomarkers in a mouse model of Fragile X Syndrome. Jonak CR; Lovelace JW; Ethell IM; Razak KA; Binder DK Neurobiol Dis; 2020 May; 138():104794. PubMed ID: 32036032 [TBL] [Abstract][Full Text] [Related]
10. Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome. Kozono N; Okamura A; Honda S; Matsumoto M; Mihara T Sci Rep; 2020 Nov; 10(1):18799. PubMed ID: 33139785 [TBL] [Abstract][Full Text] [Related]
11. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Henderson C; Wijetunge L; Kinoshita MN; Shumway M; Hammond RS; Postma FR; Brynczka C; Rush R; Thomas A; Paylor R; Warren ST; Vanderklish PW; Kind PC; Carpenter RL; Bear MF; Healy AM Sci Transl Med; 2012 Sep; 4(152):152ra128. PubMed ID: 22993295 [TBL] [Abstract][Full Text] [Related]
12. Sensory Processing Phenotypes in Fragile X Syndrome. Rais M; Binder DK; Razak KA; Ethell IM ASN Neuro; 2018; 10():1759091418801092. PubMed ID: 30231625 [TBL] [Abstract][Full Text] [Related]
13. FPT, a 2-Aminotetralin, Is a Potent Serotonin 5-HT Saraf TS; McGlynn RP; Bhatavdekar OM; Booth RG; Canal CE ACS Chem Neurosci; 2022 Dec; 13(24):3629-3640. PubMed ID: 36473166 [TBL] [Abstract][Full Text] [Related]
14. Increased aperiodic gamma power in young boys with Fragile X Syndrome is associated with better language ability. Wilkinson CL; Nelson CA Mol Autism; 2021 Feb; 12(1):17. PubMed ID: 33632320 [TBL] [Abstract][Full Text] [Related]
15. Reversal of ultrasonic vocalization deficits in a mouse model of Fragile X Syndrome with minocycline treatment or genetic reduction of MMP-9. Toledo MA; Wen TH; Binder DK; Ethell IM; Razak KA Behav Brain Res; 2019 Oct; 372():112068. PubMed ID: 31271818 [TBL] [Abstract][Full Text] [Related]
16. Deletion of Fmr1 from Forebrain Excitatory Neurons Triggers Abnormal Cellular, EEG, and Behavioral Phenotypes in the Auditory Cortex of a Mouse Model of Fragile X Syndrome. Lovelace JW; Rais M; Palacios AR; Shuai XS; Bishay S; Popa O; Pirbhoy PS; Binder DK; Nelson DL; Ethell IM; Razak KA Cereb Cortex; 2020 Mar; 30(3):969-988. PubMed ID: 31364704 [TBL] [Abstract][Full Text] [Related]
17. Developmental Changes in EEG Phenotypes in a Mouse Model of Fragile X Syndrome. Wen TH; Lovelace JW; Ethell IM; Binder DK; Razak KA Neuroscience; 2019 Feb; 398():126-143. PubMed ID: 30528856 [TBL] [Abstract][Full Text] [Related]
18. A sound-driven cortical phase-locking change in the Fmr1 KO mouse requires Fmr1 deletion in a subpopulation of brainstem neurons. Holley AJ; Shedd A; Boggs A; Lovelace J; Erickson C; Gross C; Jankovic M; Razak K; Huber K; Gibson JR Neurobiol Dis; 2022 Aug; 170():105767. PubMed ID: 35588990 [TBL] [Abstract][Full Text] [Related]
19. Abnormal development of auditory responses in the inferior colliculus of a mouse model of Fragile X Syndrome. Nguyen AO; Binder DK; Ethell IM; Razak KA J Neurophysiol; 2020 Jun; 123(6):2101-2121. PubMed ID: 32319849 [TBL] [Abstract][Full Text] [Related]
20. Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X Syndrome. Rotschafer SE; Trujillo MS; Dansie LE; Ethell IM; Razak KA Brain Res; 2012 Feb; 1439():7-14. PubMed ID: 22265702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]